Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as one of the most effective medications for weight reduction, with clinical trials showing average weight loss of 10-15% of body weight over 68 weeks. Beyond simple appetite suppression, semaglutide addresses the biological mechanisms that drive hunger and metabolic regulation. Understanding whether this medication aligns with your weight loss journey requires examining its proven benefits, realistic expectations, and how personalized factors influence outcomes.

How Semaglutide Works in Your Body for Weight Loss

Semaglutide mimics glucagon-like peptide-1, a natural hormone that regulates blood sugar, appetite, and digestive speed. When this medication activates GLP-1 receptors in the brain, it signals satiety—the feeling of fullness—and reduces cravings for high-calorie foods. This dual action means patients often eat less without experiencing the mental struggle typically associated with traditional dieting.

The medication also slows gastric emptying, which keeps food in your stomach longer and extends the sensation of fullness between meals. Additionally, semaglutide influences the brain's reward centers, making high-fat and high-sugar foods less appealing. These biological changes create a sustainable foundation for weight loss that doesn't rely solely on willpower or calorie counting.

Clinical Evidence: Real Weight Loss Results from Semaglutide Trials

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program evaluated semaglutide across four major studies involving over 4,500 participants. Patients receiving the highest dose (2.4 mg weekly) achieved an average weight loss of 15% of their baseline body weight, with some individuals losing up to 22% within one year. Participants on standard doses lost 10-12% of body weight, demonstrating consistent results across different patient populations.

Beyond weight reduction, STEP trials documented improvements in blood pressure, cholesterol levels, and fasting blood sugar—metabolic markers that predict long-term heart health. Approximately 80% of participants who lost 10% or more of their weight maintained that loss throughout the study's continuation phase, suggesting that semaglutide's effects persist when treatment continues. These outcomes represent a meaningful shift compared to older weight loss medications, which typically produced 5-7% weight reduction.

Semaglutide Cost and Accessibility: Is the Investment Worth It?

PlexusDx provides compounded semaglutide injections starting at $149 per month through licensed 503A compounding pharmacies, making treatment accessible without insurance requirements or membership fees. Your dose may need to go up as your treatment progresses—your price won't. This pricing model removes the financial barrier that prevented many patients from accessing this proven medication, and treatment qualifies for HSA and FSA accounts, reducing out-of-pocket costs further.

When comparing cost to outcomes, the investment becomes clearer: a year of semaglutide therapy costs significantly less than surgical weight loss procedures like gastric bypass, which range from $15,000 to $35,000. For patients who achieve 10-15% weight loss, the reduction in obesity-related health expenses—fewer diabetes medications, lower blood pressure medication doses, reduced cardiovascular risk—often offsets the treatment cost within two to three years. Personalization through PlexusDx's Precision Peptide Genetic Test (add-on $99 after first month) helps identify whether your genetic pathway will respond optimally, maximizing the value of your investment.

Common Side Effects and How to Manage Them

Nausea is the most frequently reported side effect in semaglutide trials, affecting 20-40% of users, though it typically diminishes after the first few weeks as your body adjusts. Gastrointestinal changes—mild constipation or diarrhea—occur in 15-25% of patients and often resolve with dietary adjustments and increased water intake. These effects are generally mild compared to older weight loss medications and rarely require treatment discontinuation.

Serious side effects are rare but include pancreatitis (inflammation of the pancreas) and diabetic retinopathy complications in people with existing eye disease. Semaglutide should not be used if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Working with PlexusDx's medical team ensures thorough screening before starting treatment and close monitoring as your dose increases, keeping you safe while maximizing therapeutic benefit.

Personalization: Genetic Testing Reveals Your Semaglutide Response Potential

Not every patient responds to semaglutide with the same magnitude of weight loss due to genetic variations in GLP-1 receptor sensitivity and metabolic pathways. PlexusDx's Precision Peptide Genetic Test examines key variants including GLP1R rs6923761 and GIPR rs1800437, which directly influence how your body responds to GLP-1 medications. Understanding your genetic predispositions helps your care team predict whether semaglutide alone will achieve your goals or whether a dual-compound approach might serve you better.

The test maps 14 distinct peptide pathways and 150+ genetic insights beyond GLP-1 response, revealing how your FTO rs9939609 and MC4R rs17782313 variants affect appetite regulation and metabolic rate. This precision approach transforms weight loss from a one-size-fits-all strategy into a truly personalized protocol. By identifying your unique genetic landscape, PlexusDx ensures you're investing in a medication strategy aligned with your biology, not just trial-and-error experimentation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How quickly will I see weight loss results from semaglutide?

Most patients begin noticing appetite reduction within the first two weeks as their dose ramps up. Measurable weight loss typically appears within four to six weeks, with momentum accelerating through weeks 8-12. Clinical trials show progressive weight loss over 68 weeks, so patience and consistency with your treatment plan yield the best long-term results.

Can I use semaglutide if I don't have diabetes?

Yes, semaglutide is FDA-approved for weight loss in people without diabetes (as Wegovy), though PlexusDx compounds semaglutide for this indication. The medication works through the same appetite-regulation mechanisms regardless of diabetes status, making it suitable for anyone seeking sustainable weight loss with medical support.

Does PlexusDx semaglutide injection work the same as brand-name Wegovy?

PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies using the same active pharmaceutical ingredient as brand medications. Compounded versions contain identical semaglutide and are held to the same quality standards, though they are not FDA-approved as a final product. Both deliver equivalent clinical outcomes when dosed appropriately and monitored by healthcare providers.

What happens to my weight if I stop taking semaglutide?

Clinical evidence shows weight regain occurs in most patients after treatment discontinuation, with some returning to baseline weight within 12-18 months. However, many retain 30-50% of weight loss long-term if they've established sustained lifestyle changes during treatment. PlexusDx emphasizes semaglutide as part of a comprehensive weight loss strategy, not a temporary fix, supporting lasting behavioral modification.

How does the Precision Peptide Genetic Test improve my semaglutide results?

The test identifies your GLP1R and GIPR genetic variants, revealing your predicted response magnitude to semaglutide. If testing shows suboptimal GLP-1 pathway activation in your genetics, your PlexusDx team may recommend dual-compound therapy or enhanced dosing strategies. This $99 add-on test prevents months of treatment uncertainty by aligning your medication to your genetic reality from the start.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves